ArticleBone & joint research2025
Comparisons of miRNA profiles of exosomes derived from human iPSCs, ADSCs, and BMSCs and effects on chondrocyte function.
Article in Bone & joint research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- FGF9 attenuates osteoarthritis progression through the NRF2/GPX3 antioxidant axis.Bone & joint research · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study aimed to identify and compare the microRNA (miRNA) profiles of exosomes derived from human induced pluripotent stem cells (iPSCs), bone marrow mesenchymal stem cells (BMSCs), and adipose tissue-derived stem cells (ADSCs) (hiPSC-Exos, hBMSC-Exos, and hADSC-Exos), and their functional effects on human articular chondrocytes (hACs). Methods: hiPSC-Exos, hBMSC-Exos, and hADSC-Exos were collected from the appropriate cells cultured in 10% bovine exosome-depleted fetal bovine serum (de-Exo-FBS) for 48 hours. Next-generation sequencing (NGS) and bioinformatics were used to analyze the small RNA profiles of these exosomes. The biological functions of hACs were examined after a 12-day treatment with exosomes. Results: hBMSC-Exos and hADSC-Exos had similar miRNA profiles but were largely different from hiPS-Exos. There were 17 highly expressed miRNAs in hiPSC-Exos, 13 miRNAs in hADSC-Exos, and 11 miRNAs in hBMSC-Exos. Among them, seven miRNAs overlapped between the hBMSC-Exos and hADSC-Exos, and only three of them (hsa-miR-16-5p, hsa-miR-25-3p, and hsa-miR-93-5p) overlapped among all three exosomes. The putative target genes of the three overlapping exosomal miRNAs, and high-scoring target genes, including MAN2A1, ZNFX1, PHF19, GPR137C, ENPP5, B3GALT2, FNIP1, PKD2, and FBXW7, were identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed that these genes are involved in cell growth, bone ossification, and cartilage development/differentiation, possibly via the mitogen-activated protein kinase (MAPK) signalling pathway. Accordingly, we confirmed the biological effect on cartilage differentiation and found that hiPSC-Exos, hBMSC-Exos, and hADSC-Exos maintained hAC viability, prevented senescence, promoted the formation of a normal cartilage matrix (glycosaminoglycan and type II collagen), and downregulated fibrocartilage matrix (type I collagen) in normal hACs. Comparatively, hBMSC-Exos had the greatest effect on hAC function. Conclusion: Bioinformatics revealed differences and possible mechanisms of action of exosomes derived from pluripotent hiPSCs, multipotent hADSCs, and multipotent hBMSCs, and these exosomes effectively suppressed cell senescence and promoted normal functional extracellular matrix formation in hACs. Further investigations of the different functions of exosomes from pluripotent-hiPSCs other than those from multipotent-hMSCs are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.